GoPath Laboratories announces today that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, GoPath's proprietary miRNA-based molecular test which predicts the potential clinical benefits associated with anti-EGFR therapy for patients with RAS wild type (WT) metastatic colorectal cancer. The new code, 0069U, is associated with an official Descriptor which states, “Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score.” This code was established following a review by the AMA’s PLA Technical Advisory Group.

This code is included in the revised set of PLA codes the AMA has released that supports the implementation of Section 216 of the Protecting Access to Medicare Act of 2014 (PAMA).  

Click here to view press release